Nanobac Pharmaceuticals, Incorporated (NNBP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2007 | 9.58 Million USD | 4.88% |
| 2006 | 9.13 Million USD | 40.45% |
| 2005 | 6.5 Million USD | 82.04% |
| 2004 | 3.57 Million USD | -60.52% |
| 2003 | 9.05 Million USD | 2514.58% |
| 2002 | 346.14 Thousand USD | 0.0% |
| 1999 | 10.69 Million USD | 10.06% |
| 1998 | 9.71 Million USD | 6.01% |
| 1997 | 9.16 Million USD | 2.69% |
| 1996 | 8.92 Million USD | 56.61% |
| 1995 | 5.7 Million USD | 46.15% |
| 1994 | 3.9 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2007 FY | 9.58 Million USD | 4.88% |
| 2007 Q1 | 7.97 Million USD | -12.73% |
| 2007 Q3 | 9.5 Million USD | 10.26% |
| 2007 Q2 | 8.61 Million USD | 8.06% |
| 2007 Q4 | 9.58 Million USD | 0.86% |
| 2006 Q4 | 9.13 Million USD | 8.42% |
| 2006 FY | 9.13 Million USD | 40.45% |
| 2006 Q1 | 7.7 Million USD | 18.39% |
| 2006 Q3 | 8.42 Million USD | 5.72% |
| 2006 Q2 | 7.97 Million USD | 3.5% |
| 2005 Q1 | 4.6 Million USD | 28.92% |
| 2005 FY | 6.5 Million USD | 82.04% |
| 2005 Q4 | 6.5 Million USD | 9.99% |
| 2005 Q3 | 5.91 Million USD | 10.01% |
| 2005 Q2 | 5.37 Million USD | 16.7% |
| 2004 Q1 | 7.52 Million USD | -16.85% |
| 2004 Q3 | 1.26 Million USD | -85.36% |
| 2004 Q4 | 3.57 Million USD | 182.49% |
| 2004 FY | 3.57 Million USD | -60.52% |
| 2004 Q2 | 8.64 Million USD | 14.85% |
| 2003 Q3 | 2.19 Million USD | 23.63% |
| 2003 FY | 9.05 Million USD | 2514.58% |
| 2003 Q1 | 291.91 Thousand USD | 0.0% |
| 2003 Q2 | 1.77 Million USD | 509.56% |
| 2003 Q4 | 9.05 Million USD | 311.41% |
| 2002 FY | 346.14 Thousand USD | 0.0% |
| 2000 Q2 | 11.74 Million USD | 2.3% |
| 2000 Q1 | 11.48 Million USD | 7.35% |
| 1999 FY | 10.69 Million USD | 10.06% |
| 1999 Q3 | 10.56 Million USD | 0.0% |
| 1999 Q4 | 10.69 Million USD | 1.21% |
| 1998 FY | 9.71 Million USD | 6.01% |
| 1997 Q1 | 11.8 Million USD | 32.19% |
| 1997 FY | 9.16 Million USD | 2.69% |
| 1996 Q1 | 5.9 Million USD | 3.51% |
| 1996 FY | 8.92 Million USD | 56.61% |
| 1996 Q3 | 8.6 Million USD | 28.36% |
| 1996 Q2 | 6.7 Million USD | 13.56% |
| 1996 Q4 | 8.92 Million USD | 3.8% |
| 1995 Q2 | 3.9 Million USD | 0.0% |
| 1995 FY | 5.7 Million USD | 46.15% |
| 1995 Q1 | 3.9 Million USD | 0.0% |
| 1995 Q3 | 4.6 Million USD | 17.95% |
| 1995 Q4 | 5.7 Million USD | 23.91% |
| 1994 FY | 3.9 Million USD | 0.0% |
| 1994 Q3 | 3.9 Million USD | 0.0% |
| 1994 Q4 | 3.9 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -34828.816% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -1.227% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 86.778% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1084.73% |
| Rebus Holdings, Inc. | 5.24 Million USD | -82.793% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 83.763% |
| Qrons Inc. | 1.48 Million USD | -543.645% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -681.432% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 87.21% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -21338.209% |
| Skye Bioscience, Inc. | 14.07 Million USD | 31.908% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 82.024% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2172.948% |
| SQZ Biotechnologies Company | 50.03 Million USD | 80.851% |
| Intellipharmaceutics International Inc. | 12 Million USD | 20.208% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -148.792% |
| Mesoblast Limited | 188.44 Million USD | 94.915% |
| Marizyme, Inc. | 26.67 Million USD | 64.08% |
| Genus plc | 485 Million USD | 98.024% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -64.002% |
| Pharming Group N.V. | 244.07 Million USD | 96.074% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -376.687% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -280.794% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -152.158% |
| ContraFect Corporation | 32.53 Million USD | 70.545% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -383.621% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -150.337% |
| IMV Inc. | 37.93 Million USD | 74.739% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 18.646% |
| MultiCell Technologies, Inc. | 1617.67 USD | -592234.778% |
| ONE Bio Corp. | 27.49 Million USD | 65.151% |
| Accustem Sciences Inc. | 1.07 Million USD | -787.85% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 87.623% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -353.036% |
| Q BioMed Inc. | 8.13 Million USD | -17.817% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 88.446% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -86.202% |
| Biomind Labs Inc. | 1.49 Million USD | -539.393% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 91.929% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -5.97% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 47.933% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -568.267% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -6643.391% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -4664.426% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -66.765% |
| GB Sciences, Inc. | 5.41 Million USD | -76.87% |
| Alpha Cognition Inc. | 7.16 Million USD | -33.738% |
| HST Global, Inc. | 593.59 Thousand USD | -1514.241% |
| CSL Limited | 18.62 Billion USD | 99.949% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -660.965% |
| Halberd Corporation | 728.71 Thousand USD | -1214.913% |
| Enzolytics Inc. | 365.26 Million USD | 97.377% |
| Agentix Corp. | 2.51 Million USD | -281.669% |
| Resverlogix Corp. | 67.39 Million USD | 85.783% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1042.441% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 97.846% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -459.044% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 61.279% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 19.5% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -161.435% |
| AVAX Technologies, Inc. | 3.99 Million USD | -139.926% |
| Zenith Capital Corp. | 27.56 Thousand USD | -34656.509% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.277% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -3915.027% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -156.594% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1307.395% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -253.366% |
| Kadimastem Ltd | 3.5 Million USD | -173.392% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -14216.697% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 80.937% |
| BioStem Technologies, Inc. | 15.9 Million USD | 39.753% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1961.985% |
| LadRx Corporation | 2.2 Million USD | -335.442% |
| Cell Source, Inc. | 15.8 Million USD | 39.38% |
| Regen BioPharma, Inc. | 5.45 Million USD | -75.572% |
| Regen BioPharma, Inc. | 5.45 Million USD | -75.572% |
| NovAccess Global Inc. | 7.86 Million USD | -21.897% |
| Affymax, Inc. | 8.87 Million USD | -8.015% |
| Itoco Inc. | 1.65 Million USD | -479.622% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -367.059% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -58.407% |
| Mobile Lads Corp. | 1.31 Million USD | -629.505% |
| CytoDyn Inc. | 127.89 Million USD | 92.508% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -22824.046% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -511.732% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 13.248% |
| SYBLEU INC | 681.41 Thousand USD | -1306.199% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -57.033% |
| International Stem Cell Corporation | 5.27 Million USD | -81.581% |
| Bioxytran, Inc. | 3.24 Million USD | -194.877% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1431.142% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -107.532% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 76.627% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 56.964% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -373.096% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -74.918% |
| Neutra Corp. | 973.52 Thousand USD | -884.256% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 66.976% |
| PureTech Health plc | 125.58 Million USD | 92.37% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -155.036% |
| IXICO plc | 1.9 Million USD | -404.239% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 53.324% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 90.726% |
| CSL Limited | 18.62 Billion USD | 99.949% |
| Cellectis S.A. | 249.36 Million USD | 96.157% |